Related Experiment Video
Updated: Aug 16, 2026

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus
A L Barry1, S D Brown, W J Novick
1Clinical Microbiology Institute, Tualatin, Oregon 97062, USA.
Abstract:
The in vitro activities of four extended-spectrum cephalosporins and benzyl penicillin were evaluated against 698 clinical isolates of Streptococcus pneumoniae, including 130 (19%) penicillin-intermediate and 84 (12%) penicillin-resistant strains. Cefotaxime and ceftriaxone were essentially identical in their antipneumococcal activities: both were active against penicillin-susceptible strains and most penicillin-intermediate strains. Cefpirome was twice as potent as cefotaxime and ceftriaxone against penicillin-resistant strains. Ceftazidime was 8- to 16-fold less active than cefotaxime and ceftriaxone against S. pneumoniae in vitro, and thus, its spectrum included only penicillin-susceptible strains.
Insights
Extended-spectrum cephalosporins show varying activity against Streptococcus pneumoniae. Cefpirome demonstrated superior potency against penicillin-resistant strains, offering a potential therapeutic option.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Streptococcus pneumoniae is a leading cause of bacterial infections worldwide.
- Increasing penicillin resistance in S. pneumoniae necessitates evaluation of alternative antibiotics.
- Extended-spectrum cephalosporins are crucial in treating pneumococcal infections.
Purpose of the Study:
- To evaluate the in vitro activity of four extended-spectrum cephalosporins and benzyl penicillin against clinical isolates of Streptococcus pneumoniae.
- To compare the efficacy of cefotaxime, ceftriaxone, cefpirome, and ceftazidime against different penicillin susceptibility profiles of S. pneumoniae.
Main Methods:
- In vitro antimicrobial susceptibility testing was performed on 698 clinical isolates of Streptococcus pneumoniae.
- Disk diffusion or broth microdilution methods were used to determine minimum inhibitory concentrations (MICs).
- Isolates were categorized based on penicillin susceptibility: susceptible, intermediate, and resistant.
Main Results:
- Cefotaxime and ceftriaxone exhibited similar activity, effective against penicillin-susceptible and most penicillin-intermediate strains.
- Cefpirome was twice as potent as cefotaxime and ceftriaxone against penicillin-resistant S. pneumoniae strains.
- Ceftazidime demonstrated significantly lower activity, with its spectrum limited to penicillin-susceptible S. pneumoniae.
Conclusions:
- Cefotaxime and ceftriaxone are effective against a broad range of S. pneumoniae, including many penicillin-intermediate strains.
- Cefpirome offers enhanced activity against penicillin-resistant S. pneumoniae, representing a valuable therapeutic option.
- Ceftazidime has limited in vitro activity against S. pneumoniae and is not recommended for these infections.
More Related Videos
06:05Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
Published on: September 30, 2014
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis